Scientists peer into the Brain's navigation center during everyday looking
NCT ID NCT07224191
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This study aims to understand how the hippocampus, a brain region key for memory and navigation, behaves when people look around and explore. Researchers will record brain activity in 56 adults with epilepsy who already have electrodes implanted for medical reasons. Participants will perform visual tasks of varying difficulty, and the results may shed light on how the brain processes spatial information.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 56 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Oct 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: All subjects: * Adults (18-70 years) * Able to provide informed consent Aim 1: Surgical epilepsy patients' inclusion criteria * Implanted hippocampal depth electrodes for Stage 1 epilepsy surgery * MMSE\>=24 Aim 2: RNS patients Inclusion criteria * Implanted RNS device with at least one hippocampal depth electrode * At least 5 months post-implantation to avoid the post-implant effect * Have a relatively low number of seizures, defined as \<1 generalized tonic-clonic or other seizure with potential to fall or cause injury per month * Able to walk and wear research equipment without assistance * MMSE\>=24 Aim 2: Healthy Control Inclusion criteria • Able to walk and wear research equipment without assistance Exclusion Criteria: RNS patients, Aim 2: • Any generalized tonic-clonic seizure within the last week All subjects: * Legally blind * Smoking tobacco, marijuana, recreational drugs or alcohol use within 1 week of cognitive testing * Unable to give informed consent * Pregnancy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Epilepsy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can lavender and lullabies help kids with epilepsy sleep better?
- Reading the Brain's signals to predict who benefits from deep brain stimulation
- Can a Comfort-Focused education program improve life with epilepsy?
- Can video games rewire young brains after injury?
- High-Fat Diet's effect on epilepsy: scientists track brain signals
- Epilepsy drug candidate put to the test in healthy volunteers